Cardiovascular AI Startup Corologic Secures Seed Funding from Kakao Ventures and Seoul National University Holdings

Corologic, a cardiovascular imaging artificial intelligence (AI) startup, is set to pursue multicenter clinical validation following its recent seed investment round.

On September 15, Corologic announced that it has secured seed investment from Kakao Ventures and Seoul National University Holdings. Established in May by Professor Kang Si-hyuk’s cardiology team at Seoul National University Bundang Hospital, Corologic is developing an AI solution called 'Angio-FILM' that is designed to reduce radiation exposure for both patients and medical staff during coronary angiography procedures.

Angio-FILM utilizes AI-powered video frame interpolation (VFI) technology to restore low-frame-rate coronary angiography videos in real time, making them appear as high-frame-rate videos. The AI analyzes the position and movement of vessels and medical devices by comparing preceding and following frames of continuous video, then estimates the intermediate frames that would exist between them, generating new frames accordingly. This approach allows medical professionals to continuously observe vascular motion and procedural progress with fewer X-ray captures, enhancing clinical efficiency and safety.

A key advantage of Angio-FILM is that it can be implemented without replacing existing angiography equipment. The solution is added to current procedural environments and can interface seamlessly with hospital imaging systems, employing an edge processing model to handle videos in real time within the hospital. Because it integrates with existing healthcare infrastructures without requiring large-scale equipment upgrades, Corologic anticipates that the solution will reduce the burden of adoption for medical institutions.

With the funds raised in this investment round, Corologic plans to conduct multicenter clinical trials, pursue regulatory approvals from the Ministry of Food and Drug Safety (MFDS) of Korea as well as 510(k) clearance from the U.S. Food and Drug Administration (FDA), and obtain global quality certification (ISO 13485). By doing so, the company aims to demonstrate product reliability and establish a foundation that will allow domestic and international healthcare institutions to promptly deploy or collaborate on-site with its system.

Jung Juyoun, Senior Investment Manager at Kakao Ventures, commented, "Because Angio-FILM is an independent solution that is not tied to any specific equipment manufacturer, it has strong potential for global scalability. We expect Corologic to emerge as a leading company improving clinical environments through generative AI."

This content was produced with the assistance of AI translation services.